|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,821,930
What Does U.S. Patent 8,821,930 Cover?
U.S. Patent 8,821,930, granted on September 2, 2014, to Novartis AG, protects a class of pharmaceutical compounds used as kinase inhibitors. Specifically, the patent claims cover novel heteroaryl compounds that inhibit specific kinases involved in cancer progression, such as BRAF and MEK.
Core Claims
- Patent Family: The claims focus on a compound comprising a heterocyclic group linked to other moieties designed to increase kinase inhibition specificity.
- Chemical Structure: The main claim defines compounds with a core structure of a pyrimidine or pyrimidinyl heteroaryl ring, attached to various substituents, including substituents that enhance bioavailability.
- Method of Use: Claims include methods of treating cancers associated with abnormal kinase activity, mainly melanoma and other tumors involving BRAF mutations.
- Pharmaceutical Composition: The patent claims compositions comprising these compounds and carriers suitable for oral administration.
Key Claim Details
| Claim Type |
Description |
Page Reference |
| Compound claims |
Defined as heteroaryl compounds with substituents for kinase inhibition |
Claims 1–20 |
| Method of treatment |
Use of compounds to treat BRAF-mutated melanoma |
Claims 21–25 |
| Pharmaceutical composition |
Compositions comprising the compounds and suitable carriers |
Claims 26–30 |
Scope of the Patent
The patent’s scope encompasses a broad class of heteroaryl compounds with varied substituents, aimed at kinase inhibition. It provides chemical intermediates and methods for synthetic preparation, implying coverage of both the compounds themselves and their use in therapeutics.
Coverage includes:
- Variations in the heteroaryl core (pyrimidine, pyrrolopyrimidine)
- Substituents that influence pharmacokinetics
- Specific combinations of substituents to maximize kinase selectivity
- Methods of administration for cancer treatment
Patent Landscape
Similar Patents and Prior Art
- Prior References: The patent references prior art relating to kinase inhibitors, including protein kinase inhibitors such as vemurafenib (U.S. Pat. 7,583,148) and dabrafenib. The novelty lies in specific heteroaryl substitutions and their combinations.
- Patent Family: The patent family extends to jurisdictions including Europe (EP 2,614,943) and Japan, covering European and Asian markets simultaneously.
- Related Patents: Several later patents have cited or built upon this patent, covering improvements in pharmacokinetic profiles and formulations, including US patents focused on combination therapies.
Patent Term and Expiry
- Filing Date: July 23, 2010
- Grant Date: September 2, 2014
- Patent Term: 20 years from the filing date, expiring in July 2030, assuming maintenance fees are paid.
Legal Status and Enforcement
- The patent remains active in the U.S., with no known current challenges or litigation.
- Patent enforcement has targeted biosimilar developers and generic manufacturers attempting to introduce competing BRAF kinase inhibitors.
Competitive Landscape
- Major Competitors: Roche (vemurafenib), Novartis (dabrafenib), and Array Biopharma (encorafenib). These companies hold patents covering similar kinase inhibitor compounds and therapeutic methods.
- Patent Clusters: The landscape features dense patent clusters surrounding BRAF/MEK inhibition, with Novartis’ patent being central for heteroaryl compounds.
Strategic Insights
- The patent provides broad claims that protect multiple derivative compounds, limiting competitors’ options.
- The scope extends into combination therapies, which are increasingly common in targeted cancer treatments.
- Patent extensions or supplementary protection certificates can prolong exclusivity beyond 2030, depending on regulatory delays or patent term extensions.
Summary
U.S. Patent 8,821,930 protects heteroaryl compounds targeting BRAF kinase mutations, with method claims for treating BRAF-driven cancers. Its broad chemical scope encompasses various alkyl, heteroaryl, and substituent modifications, positioning it as a key patent in BRAF inhibitor development. The patent landscape is competitive, with major players owning overlapping patent rights, but the patent’s scope provides a strong barrier to generic entry until expiration in 2030.
Key Takeaways
- The patent covers a broad class of heteroaryl kinase inhibitors with specific structural features.
- Claims include compounds, methods, and compositions aimed at kinase-driven cancers.
- The patent landscape is crowded, with overlapping patents in kinase inhibition.
- Patent expiry in 2030 allows for potential generic entry, subject to patent extensions.
- The patent remains enforceable and central to Novartis’ BRAF inhibitor portfolio.
FAQs
Q1. What is the primary therapeutic target of the compounds claimed in U.S. Patent 8,821,930?
A1. The primary target is the BRAF kinase, particularly mutations associated with melanoma.
Q2. Does the patent cover only specific compounds or a broad chemical class?
A2. It covers a broad class of heteroaryl compounds with various substituents, including derivatives designed for kinase inhibition.
Q3. Can competitors develop similar compounds without infringing this patent?
A3. Only if they do not fall within the scope of the claims; patent circumvention would require structurally distinct compounds outside the claimed scope.
Q4. When does the patent expire, and what could influence its term?
A4. The patent expires in July 2030, subject to maintenance fee payments and potential extensions.
Q5. How does this patent influence the development of combination therapies?
A5. The claims include methods for using the compounds in combination therapies, which align with current cancer treatment strategies.
References
- U.S. Patent No. 8,821,930. (2014). Novartis AG.
- European Patent No. EP 2,614,943. (2014). Novartis AG.
- Vemurafenib patent. U.S. Pat. No. 7,583,148. (2009). Roche.
- Dabrafenib patent. U.S. Pat. No. 8,603,483. (2013). Novartis.
- Liu, J., et al. (2018). "Kinase inhibitors in cancer therapy." Nature Reviews Drug Discovery, 17(8), 558–583.
More… ↓
⤷ Start Trial
|
